JP6519478B2 - 抗htlv抗体の免疫測定における非特異反応の低減方法 - Google Patents
抗htlv抗体の免疫測定における非特異反応の低減方法 Download PDFInfo
- Publication number
- JP6519478B2 JP6519478B2 JP2015546653A JP2015546653A JP6519478B2 JP 6519478 B2 JP6519478 B2 JP 6519478B2 JP 2015546653 A JP2015546653 A JP 2015546653A JP 2015546653 A JP2015546653 A JP 2015546653A JP 6519478 B2 JP6519478 B2 JP 6519478B2
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- htlv
- modified
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010029719 Nonspecific reaction Diseases 0.000 title claims description 34
- 238000003018 immunoassay Methods 0.000 title claims description 34
- 238000000034 method Methods 0.000 title claims description 32
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 claims description 51
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 48
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 32
- 150000001413 amino acids Chemical class 0.000 claims description 29
- 229920001184 polypeptide Polymers 0.000 claims description 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 239000003638 chemical reducing agent Substances 0.000 claims description 15
- 238000006467 substitution reaction Methods 0.000 claims description 15
- 230000035772 mutation Effects 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- -1 amino acid amino acid Chemical class 0.000 claims description 4
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims 3
- 239000000427 antigen Substances 0.000 description 45
- 102000036639 antigens Human genes 0.000 description 45
- 108091007433 antigens Proteins 0.000 description 45
- 235000001014 amino acid Nutrition 0.000 description 26
- 239000002245 particle Substances 0.000 description 18
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 241000700605 Viruses Species 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000002372 labelling Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 239000004816 latex Substances 0.000 description 4
- 229920000126 latex Polymers 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 230000004520 agglutination Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000006249 magnetic particle Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 101800000385 Transmembrane protein Proteins 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 108700004026 gag Genes Proteins 0.000 description 2
- 101150098622 gag gene Proteins 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 101800000504 3C-like protease Proteins 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 101710147327 Calcineurin B homologous protein 1 Proteins 0.000 description 1
- 101710205625 Capsid protein p24 Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101710177166 Phosphoprotein Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 101710149279 Small delta antigen Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012767 chemiluminescent enzyme immunoassay Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 101800000607 p15 Proteins 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 101150045694 prt gene Proteins 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
Description
p19のC末端領域(aa103-130)は、HTLV-1抗体検査で抗原として利用可能であることが知られている。この領域内で非特異反応の吸収に重要な領域を特定するため、表1に示すp19断片を化学合成により調製し、非特異反応を生じることが確認されている非特異検体を用いて非特異反応の吸収試験を行なった。
非特異責任配列中の残基を1つずつアラニンで置換した改変p19ペプチド(表3)を作製し、上記と同様に非特異吸収試験を実施した。
ポジティブコントロールの測定値の低下が少ないNo.36とNo.39のペプチドを選択し、下記表5の通りさらに変異ペプチドを調製した(N末端のKは、そのアミノ基を介してカルボキシル化粒子に固定するためにペプチドに付加した)。
(1) カルボキシル化磁性粒子(富士レビオ社製)15 mgをMilliQ水で3回洗浄した。
(2) EDC(1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride)4 mgを添加し、25℃で30分間ゆるやかに攪拌しながらインキュベートした。
(3) 改変p19ペプチド7.5 mgを添加し、25℃で60分間ゆるやかに攪拌しながらインキュベートした。
(4) 2% BSA/Tris (pH 7.2)で3回洗浄し、これを改変p19ペプチド感作粒子とした。
Claims (10)
- 抗HTLV抗体の免疫測定における非特異反応の低減方法であって、抗原抗体反応系内に改変p19ペプチドを存在させることを含み、前記改変p19ペプチドは、HTLV p19のうちの第103番〜第130番アミノ酸の領域を含むp19断片で構成され、かつ、p19の第112番〜第118番アミノ酸に該当する領域内に少なくとも1つの置換変異を有するポリペプチドである、方法。
- 前記改変p19ペプチドは、p19の第114番アミノ酸及び第117番アミノ酸に該当するアミノ酸残基の少なくともいずれか一方における置換変異を含む、請求項1記載の方法。
- 前記改変p19ペプチドは、配列番号2〜15のいずれかに示されたアミノ酸配列で構成されるポリペプチドである、請求項1記載の方法。
- 前記改変p19ペプチドは、配列番号17〜25のいずれかに示されたアミノ酸配列からなるポリペプチドである、請求項2記載の方法。
- 前記改変p19ペプチドが固相支持体上に固定化されている、請求項1ないし4のいずれか1項に記載の方法。
- 改変p19ペプチドを含む、抗HTLV抗体の免疫測定試薬であって、前記改変p19ペプチドは、HTLV p19のうちの第103番〜第130番アミノ酸の領域を含むp19断片で構成され、かつ、p19の第112番〜第118番アミノ酸に該当する領域内に少なくとも1つの置換変異を有するポリペプチドである、免疫測定試薬。
- 改変p19ペプチドを含む、抗HTLV抗体の免疫測定用の非特異反応低減剤であって、前記改変p19ペプチドは、HTLV p19のうちの第103番〜第130番アミノ酸の領域を含むp19断片で構成され、かつ、p19の第112番〜第118番アミノ酸に該当する領域内に少なくとも1つの置換変異を有するポリペプチドである、非特異反応低減剤。
- 請求項6記載の免疫測定試薬又は請求項7記載の非特異反応低減剤を含む、抗HTLV抗体の免疫測定キット。
- 配列番号2〜15のいずれかに示されたアミノ酸配列で構成される、人工のポリペプチド。
- 配列番号17〜25のいずれかに示されたアミノ酸配列からなる、人工のポリペプチド。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013229924 | 2013-11-06 | ||
JP2013229924 | 2013-11-06 | ||
PCT/JP2014/079301 WO2015068715A1 (ja) | 2013-11-06 | 2014-11-05 | 抗htlv抗体の免疫測定における非特異反応の低減方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2015068715A1 JPWO2015068715A1 (ja) | 2017-03-09 |
JP6519478B2 true JP6519478B2 (ja) | 2019-05-29 |
Family
ID=53041492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015546653A Active JP6519478B2 (ja) | 2013-11-06 | 2014-11-05 | 抗htlv抗体の免疫測定における非特異反応の低減方法 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3067697B1 (ja) |
JP (1) | JP6519478B2 (ja) |
WO (1) | WO2015068715A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180246121A1 (en) * | 2015-08-21 | 2018-08-30 | Fuso Pharmaceutical Industries, Ltd. | Immunological test method and immunological test kit |
US11174310B2 (en) | 2016-10-26 | 2021-11-16 | Fuso Pharmaceutical Industries, Ltd. | Disulfide-type HMGB1-specific antibody, method for measuring disulfide-type HMGB1 and kit for said measurement, and measurement method capable of quantitating all of HMGB1 molecules including reduced HMGB1, disulfide-type HMGB1 and thrombin-cleavable HMGB1 and kit for said measurement |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2979414B2 (ja) | 1989-09-29 | 1999-11-15 | 富士レビオ株式会社 | 磁性粒子およびそれを用いた免疫測定法 |
NZ238855A (en) * | 1990-07-18 | 1994-03-25 | Iaf Biochem Int | Peptides, mixtures thereof and compositions useful for detecting htlv-i and htlv-ii infections |
CA2117378C (en) | 1992-02-24 | 2003-04-15 | Steven K. H. Foung | Htlv-i/htlv-ii assay and method |
JP2000078973A (ja) * | 1998-09-03 | 2000-03-21 | Tonen Corp | Htlv−i組換え抗原 |
JP4879067B2 (ja) * | 2007-03-30 | 2012-02-15 | シスメックス株式会社 | 免疫測定用検体前処理液、免疫測定用試薬キット及び免疫測定方法 |
-
2014
- 2014-11-05 EP EP14859384.1A patent/EP3067697B1/en not_active Not-in-force
- 2014-11-05 WO PCT/JP2014/079301 patent/WO2015068715A1/ja active Application Filing
- 2014-11-05 JP JP2015546653A patent/JP6519478B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JPWO2015068715A1 (ja) | 2017-03-09 |
EP3067697B1 (en) | 2019-05-08 |
EP3067697A1 (en) | 2016-09-14 |
WO2015068715A1 (ja) | 2015-05-14 |
EP3067697A4 (en) | 2017-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111978378A (zh) | SARS-CoV-2抗原多肽及其应用 | |
US20180348212A1 (en) | Method for detecting test substance and reagent kit for detecting test substance | |
JP5611831B2 (ja) | リウマチ性関節炎自己抗体との免疫反応性合成ペプチド | |
US20070259336A1 (en) | Methods for the detection of analytes in a sample | |
CA2965189C (en) | A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens | |
JP6519478B2 (ja) | 抗htlv抗体の免疫測定における非特異反応の低減方法 | |
AU2006223631B2 (en) | Method and device for detecting feline immunodeficiency virus | |
WO1991013360A1 (en) | NEW HIV p24 PEPTIDES, DIAGNOSTIC ANTIGENS AND DISCRIMINATIVE IMMUNOASSAY METHOD | |
JP5712513B2 (ja) | ヒトサイトメガロウイルス感染の検出方法 | |
JP4975601B2 (ja) | Hcv抗体測定用試薬キット及びhcv抗体測定方法 | |
JP2018070454A (ja) | 糖ペプチドと反応するモノクローナル抗体およびその用途 | |
CN114478716B (zh) | 一种多肽组合及其在新型冠状病毒抗体检测中的应用 | |
EP1978365B1 (en) | Reagent kit and method for measuring HCV antibody | |
JP2000002707A (ja) | Env/gagポリペプチドマ―カ―を使用するネコ免疫不全ウイルス感染の診断 | |
TW201337268A (zh) | 一種偵測c型肝炎病毒感染之方法 | |
CN108948174B (zh) | 一种瓜氨酸修饰肽及其应用 | |
CN108948173B (zh) | 一种瓜氨酸修饰肽及其应用 | |
JP4961577B2 (ja) | アレルギーを診断するエピトープポリペプチド | |
WO2010123083A1 (ja) | マウス肝炎ウイルス由来ポリペプチドおよび/またはセンダイウイルス由来ポリペプチド、これらを用いたマウス肝炎ウイルス感染および/またはセンダイウイルス感染検査キット、ならびにマウス肝炎ウイルス感染および/またはセンダイウイルス感染の検出方法 | |
Brown et al. | Optimisation of a peptide-based indirect ELISA for the detection of antibody in the serum of HIV-1 seropositive patients | |
JP4975600B2 (ja) | Hcv抗体測定用試薬キット及びhcv抗体測定方法 | |
CN113563479B (zh) | 包虫病诊断试剂盒 | |
CN113447657B (zh) | 一种检测抗乌头酸水合酶-IgG抗体的检测试剂盒 | |
CN116679055A (zh) | 一种用于类风湿关节炎的诊断标志物及其检测芯片和应用 | |
JP2015215244A (ja) | 免疫測定における抗htlv抗体の検出感度を向上させる方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171006 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180918 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181105 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190326 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190408 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6519478 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |